Business
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
CAMBRIDGE, Mass., June 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., June 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.\n\n \n \n \n \n \n \n\n \nA webcast of the presentation can be accessed through the \"Investors\" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.\nAbout Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.\nAkebia Therapeutics ContactMercedes [email protected]\n \n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-hc-wainwright-3rd-annual-kidney-virtual-conference-302184495.html\nSOURCE Akebia Therapeutics, Inc.","length":3953,"tagName":"div"}]